Table 2. Virological suppression status of children receiving ART stratified by socio-demographic and ART characteristics.
| Characteristics | Non-suppressed N = 69 (23%) | Suppressed N = 231 (77%) | p-value |
|---|---|---|---|
| Sex | |||
| Male | 31 (23.7) | 100(76.3) | |
| Female | 38 (22.5) | 131(77.5) | 0.81 |
| TB-status | |||
| No | 59 (22.0) | 208 (78.0) | |
| Yes | 10 (30.3) | 23(69.7) | 0.291 |
| WHO stage at ART initiation | |||
| Stage 1 | 22 (19.0) | 94 (81.0) | |
| Stage 2 | 16(13.5) | 103(86.6) | 0.000 |
| Stage 3 | 15(33.3) | 30(66.7) | |
| Stage 4 | 16(80.0) | 4 (20.0) | |
| ART Regimen | |||
| Efavirenz-based | 24(21.0) | 91(79.1) | |
| Nevirapine-based | 19(21.4) | 70 (78.7) | |
| Lopinavir/r based | 26(27.1) | 70 (73.0) | 0.513 |
| ART-induced side-effects | |||
| No | 52 (19.0) | 222 (81.0) | |
| Yes | 17 (65.4) | 9(34.6) | 0.000 |
| Age at ART initiation | |||
| 0–4 years | 30 (47.0) | 34 (53.1) | |
| 5–9 years | 28(19.3) | 117 (80.7) | |
| 10–14 years | 11 (12.1) | 80 (88.0) | 0.000 |
| ART adherence level | |||
| Poor (40%-84%) | 8 (25.8) | 23 (74.2) | |
| Medium (85%-94%) | 3(43.0) | 4(57.1) | |
| High (95%-100%) | 58(22.0) | 204(78.0) | 0.405 |